McLaughlin-Rotman Centre for Global Health, at the University Health Network and University of Toronto, MaRS Centre, South Tower, Suite 406, 101 College Street, Toronto, Ontario, M5G 1L7, Canada.
BMC Int Health Hum Rights. 2010 Dec 13;10 Suppl 1(Suppl 1):S5. doi: 10.1186/1472-698X-10-S1-S5.
Uganda has a long history of health research, but still faces critical health problems. It has made a number of recent moves towards building science and technology capacity which could have an impact on local health, if innovation can be fostered and harnessed.
Qualitative case study research methodology was used. Data were collected through reviews of academic literature and policy documents and through open-ended, face-to-face interviews with 30 people from across the science-based health innovation system, including government officials, researchers in research institutes and universities, entrepreneurs, international donors, and non-governmental organization representatives.
Uganda has a range of institutions influencing science-based health innovation, with varying degrees of success. However, the country still lacks a coherent mechanism for effectively coordinating STI policy among all the stakeholders. Classified as a least developed country, Uganda has opted for exemptions from the TRIPS intellectual property protection regime that include permitting parallel importation and providing for compulsory licenses for pharmaceuticals. Uganda is unique in Africa in taking part in the Millennium Science Initiative (MSI), an ambitious though early-stage $30m project, funded jointly by the World Bank and Government of Uganda, to build science capacity and encourage entrepreneurship through funding industry-research collaboration. Two universities - Makerere and Mbarara - stand out in terms of health research, though as yet technology development and commercialization is weak. Uganda has several incubators which are producing low-tech products, and is beginning to move into higher-tech ones like diagnostics. Its pharmaceutical industry has started to create partnerships which encourage innovation.
Science-based health product innovation is in its early stages in Uganda, as are policies for guiding its development. Nevertheless, there is political will for the development of STI in Uganda, demonstrated through personal initiatives of the President and the government's willingness to invest heavily for the long term in support of STI through the Millennium Science Initiative. Activities to support technology transfer and private-public collaboration have been put in motion; these need to be monitored, coordinated, and learned from. In the private sector, there are examples of incremental innovation to address neglected diseases driven by entrepreneurial individuals and South-South collaboration. Lessons can be learned from their experience that will help support Ugandan health innovation.
乌干达在医学研究方面有着悠久的历史,但仍面临着严峻的健康问题。它最近采取了一些措施来建设科技能力,如果能够促进和利用创新,这可能会对当地的健康产生影响。
采用定性案例研究方法。通过对学术文献和政策文件的审查,以及对来自整个基于科学的健康创新系统的 30 人的开放式、面对面访谈,收集了数据。这些人包括政府官员、研究机构和大学的研究人员、企业家、国际捐助者和非政府组织代表。
乌干达拥有一系列影响基于科学的健康创新的机构,这些机构的成功程度各不相同。然而,该国仍然缺乏一个有效的协调机制,无法在所有利益相关者之间有效地协调科学、技术和创新政策。作为最不发达国家,乌干达选择了对知识产权保护的《与贸易有关的知识产权协定》(TRIPS)豁免,其中包括允许平行进口和为药品提供强制许可。乌干达在非洲是独一无二的,它参与了千年科学倡议(MSI),这是一个雄心勃勃但处于早期阶段的 3000 万美元项目,由世界银行和乌干达政府共同资助,通过资助行业-研究合作来建设科学能力和鼓励创业精神。两所大学——马凯雷雷大学和姆巴拉拉大学——在健康研究方面表现出色,但迄今为止,技术开发和商业化仍很薄弱。乌干达有几个孵化器,它们正在生产低技术产品,并开始进入更高技术的产品,如诊断。其制药业已开始建立鼓励创新的伙伴关系。
乌干达的基于科学的卫生产品创新仍处于早期阶段,指导其发展的政策也处于早期阶段。尽管如此,乌干达还是有发展科学、技术和创新的政治意愿,这一点体现在总统的个人倡议和政府愿意长期投资,通过千年科学倡议支持科学、技术和创新。支持技术转让和公私合作的活动已经启动;这些需要进行监测、协调和总结经验。在私营部门,有一些企业家个人和南南合作驱动的针对被忽视疾病的渐进式创新的例子。可以从他们的经验中吸取教训,帮助支持乌干达的卫生创新。